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Summary
 
Lymphotoxin (LT) is widely regarded as a proinflammatory cytokine with activities equivalent
to tumor necrosis factor (TNF). The contribution of LT to experimental autoimmune enceph-
alomyelitis (EAE) was examined using TNF/LT
 
a
 
2/2 
 
mice, TNF
 
2/2
 
 mice, and a new LT
 
a
 
2/2
 
line described here. All mice were generated directly in the C57BL/6 strain and used for the
preparation of radiation bone marrow chimeras to reconstitute peripheral lymphoid organs and
restore immunocompetence. This approach overcame the problems related to the lack of
lymph nodes that results from LT
 
a
 
 gene targeting. We show here that when LT is absent but
TNF is present, EAE progresses normally. In contrast, when TNF is absent but LT is present,
EAE is delayed in onset and inflammatory leukocytes fail to move normally into the central
nervous system parenchyma, even at the peak of disease. In the absence of both cytokines, the
clinical and histological picture is identical to that seen when TNF alone is deficient, including
demyelination. Furthermore, the therapeutic inhibition of TNF and LT
 
a
 
 with soluble TNF
receptor in unmanipulated wild-type or TNF
 
2/2
 
 
 
mice exactly reproduces these outcomes. We
conclude from these studies that TNF and LT are functionally distinct cytokines in vivo, and
despite sharing common receptors, show no redundancy of function nor mutual compensation. 
 
L
 
ymphotoxin (LT)
 
1
 
, like TNF, is considered to be a
proinflammatory, cytotoxic cytokine (1) and critical
mediator of lymphocyte-dependent autoimmune patholo-
gies such as multiple sclerosis (MS) and the MS animal
model, experimental autoimmune encephalomyelitis (EAE;
for review see reference 2). Evidence for a key role of LT
in MS and EAE comes from four types of experiments.
First, LT is identified within the lesions of MS (3, 4) and
EAE (5). Second, the encephalitogenicity of T cells is asso-
ciated with their ability to synthesize LT (6–8), although
this association is not absolute (9). Third, LT is toxic to oli-
godendrocytes in culture (10). Fourth, LT
 
 
 
and TNF block-
ade prevents or ameliorates disease (11–13).
LT in its secreted form (LT
 
a
 
3
 
) is thought to contribute
to pathologies of this kind by its ability to bind to TNFR1
and TNFR2 (1, 14), resulting in the promotion of inflam-
mation by the upregulation of endothelial adhesion mole-
cules (15) and the delivery of cytotoxic signals to target
cells (16). Furthermore, LT
 
a
 
 in association with the related
cell surface molecule LT
 
b
 
 
 
(LT
 
a
 
1
 
b
 
2
 
; references 17, 18),
binds the LT
 
b
 
 receptor (19) in a system found to be essen-
tial for normal peripheral lymphoid development (20, 21),
and is capable of delivering a cytotoxic signal to target cells
(22).
Until recently, the means to test the relative contribu-
tions of LT and TNF to inflammatory processes have not
been available. TNF (23), TNF/LT
 
a
 
 (24), LT
 
a
 
, and LT
 
b
 
(25) gene-targeted mice have now been used to address this
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; ES, embryonic stem; iNOS, in-
ducible nitric oxide synthase; LT, lymphotoxin; MOG, myelin oligoden-
drocyte glycoprotein; MS, multiple sclerosis; RAG, recombinase activation
gene; RT-PCR, reverse transcriptase PCR; TNFR–IgG, TNFR–human
IgG fusion protein; WT, wild type. Radiation bone marrow chimeras:
WT
 
®
 
WT, WT bone marrow transplanted into WT recipients;
WT
 
®
 
RAG, WT bone marrow transplanted into RAG-1
 
2/2
 
 recipients;
LT
 
®
 
RAG, LT
 
a
 
2/2
 
 bone marrow transplanted into RAG-1
 
2/2
 
 recipi-
ents; TNF
 
®
 
RAG, TNF
 
2/2
 
 bone marrow transplanted into RAG-1
 
2/2
 
recipients; TNF
 
®
 
TNF, TNF
 
2/2
 
 bone marrow transplanted into TNF
 
2/2
 
recipients; TNF/LT
 
®
 
TNF, TNF/LT
 
a
 
2/2
 
 bone marrow transplanted
into TNF
 
2/2
 
 recipients.
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question. In the latter two studies using the EAE disease
model, opposite conclusions have been drawn about the
role of LT. In the first of these (24), it was argued that nei-
ther LT nor TNF play any role in EAE, and in the second
(25), that secreted LT
 
a
 
3
 
 
 
is critical in the pathogenesis of this
disease. The direct use of LT
 
a
 
 or LT
 
b
 
 gene-deleted mice
for studies of immune pathology, however, is compro-
mised by the immune deficiencies that follow, for example,
the absence of peripheral lymph nodes in these mice (20,
26). The fact that control animals in these two studies had
normal immune systems necessarily implies that any differ-
ences observed in experimental outcomes between wild-
type (WT) and LT-negative mice cannot be attributed to
the activities of the cytokine alone. The difficulty in inter-
pretation of these experiments is compounded by the fact
that the TNF, LT
 
a
 
, and LT
 
b
 
 genes are located within the
MHC (27)
 
.
 
 The backcrossing of 129 strain gene-deleted
mice onto EAE-susceptible strains, such as SJL or C57BL/6,
would create partial chromosome 17 congenics that differ
from WT controls in this fundamentally important disease
susceptibility locus (28). For these reasons, we regard the
question of the relative contribution of LT to EAE patho-
genesis to be unresolved.
 We have disrupted the TNF and LT
 
a
 
 genes directly in
C57BL/6 mice (29), a strain that is highly susceptible to
EAE induced by immunization with the 35–55 peptide of
myelin oligodendrocyte glycoprotein (MOG). This avoids
the problem of genetic heterogeneity introduced by back-
crossing. In the first series of experiments using TNF
 
2/2
 
mice (23), direct immunization was possible because pe-
ripheral immunity in these mice was essentially intact. The
clinical course and pathological changes of EAE in TNF
 
2/2
 
mice were remarkable, revealing key activities for this cy-
tokine in the initiation of inflammatory lesions and the
control of leukocyte movement within the central nervous
system (CNS). 
To extend these experiments to the role of LT in EAE,
the problem of immunocompetence had to be accounted
for. Unlike TNF, LT is predominantly, if not exclusively, a
product of leukocytes (14) and particularly, Th1 T cells
(30). It is LT produced from these hemopoietically derived
sources that is thought to be crucial in CNS autoimmune
inflammatory lesions
 
 
 
(6, 8). Bone marrow cells derived
from LT
 
a
 
2/2
 
 
 
mice have the capacity to repopulate lymph
nodes in irradiated recipient animals (31). Therefore, chi-
meras may be generated that are LT deficient, but with a
reconstituted functional immune system. 
In a second series of experiments reported here, bone
marrow cells from a newly generated LT
 
a
 
2/2
 
 C57BL/6
strain (see Results), in combination with previously de-
scribed TNF
 
2/2
 
 and TNF/LT
 
a
 
2/2
 
 C57BL/6 mice (29),
were used to reconstitute peripheral lymphoid structures in
lethally irradiated recipient animals. This enabled the appli-
cation of a standard EAE induction protocol to all mice and
the study of the activities of LT both in the presence and
absence of TNF. Furthermore, inhibition of TNF and LT
 
a
 
3
 
by a soluble TNFR–human IgG fusion protein (TNFR–IgG)
 
in WT and TNF
 
2/2
 
 mice represents the first direct com-
parison of the effects of gene targeting and therapeutic in-
hibition in a single disease model. Using these experimental
systems, we reveal the lack of any unique contribution by
LT to clinical manifestations of disease, CNS inflammation,
or demyelination. In addition, we demonstrate that the
profound role of TNF in the control of normal inflamma-
tory cell movement within the CNS (23) is not shared by LT.
 
Materials and Methods
 
Animals.
 
C57BL/6.TNF
 
2/2
 
, C57BL/6.TNF/LT
 
a
 
2/2
 
 (29),
and C57BL/6.LT
 
a
 
2/2
 
 mice were generated and bred in-house
under specific pathogen-free conditions (Centenary Institute,
Sydney, Australia). WT C57BL/6 (Ly5.2), C57BL/6.Ly5.1, and
C57BL/6.RAG-1
 
2/2
 
 
 
(RAG, recombinase activation gene) mice
(32) were obtained from Animal Resource Centre (Perth, Australia).
Adult (
 
.
 
6 wk old) female mice were used in all experiments. All
animal procedures were approved by the Animal Care and Ethics
Committee of the University of Sydney (Sydney, Australia).
 
Generation of C57BL/6 Strain LT
 
a
 
2
 
/
 
2
 
 Mice.
 
A DraI fragment
encompassing the genes encoding for LT
 
a
 
 and TNF was derived
from a C57BL/6 genomic DNA clone (Fig. 1 
 
A
 
) comprising TNF,
LT
 
a
 
, and LT
 
b
 
 (33; obtained from C.V. Jongeneel, Ludwig Insti-
tute for Cancer Research, Lausanne, Switzerland), and cloned
into the SmaI site of pUC 19 (GIBCO BRL, Paisley, UK). A neo-
mycin resistance cassette was inserted in sense direction into an
unique ApaI site in exon 2 of the LT
 
a
 
 gene to create the target-
ing vector (Fig. 1
 
 A
 
), with total length of homology of 6,580
bases (1,549 bases: 5
 
9
 
 homology; 5,031 bases: 3
 
9
 
 homology). The
C57BL/6 embryonic stem (ES) cell line Bruce 4 (provided by F.
Köntgen, Walter and Eliza Hall Institute, Melbourne, Australia;
reference 34) was cultured on neomycin resistance embryonic fi-
broblasts (35), and transfected, cloned, and screened by nested set
PCR following standard procedures (36). LT
 
a
 
1/2
 
 C57BL/6 ES
cells were injected into recipient BALB/c blastocysts matured in
vitro
 
 
 
(37), and embryos were reimplanted into pseudopregnant
(C57BL/6 
 
3
 
 BALB/c) F1 foster mothers. All chimeric animals
were mated to C57BL/6 partners and germ line transmission was
detected by coat color. The presence of the targeted allele was
confirmed by Southern blot (Fig. 1 
 
B
 
). The established LT
 
a
 
2/2
 
mouse line was maintained on a pure C57BL/6 background.
 
Southern Blot, Nested Set PCR, and Reverse Transcriptase PCR.
 
Genomic DNA was purified from ES cells according to standard
procedures (38) or from white blood cells using a genomic DNA
kit (Promega Corp., Madison, WI). To detect homologous re-
combination, nested set PCR was performed with an outer
primer pair (5
 
9
 
 sense: CTA GGA CAG GGT TCT CAA CCT
TCC T; 3
 
9
 
 antisense: CCA GTC CCT TCC CGC TTC AGT
GAC AAC GTC; 20 cycles) followed by another round of am-
plification with an inner primer pair (5
 
9
 
 sense: CAG TTC CTC
ATG TTG TGG TGA CCC; 3
 
9
 
 antisense: CCG ACT GCA
TCT GCG TGT TCG A; 35 cycles). The annealing temperature
was 60
 
8
 
C for both primer pairs. The Southern blot strategy used
the introduction of an additional PstI site into the genome within
the neomycin resistance cassette (29). Successfully targeted alleles
showed a fragment length of 6.4 kb (WT 9.4 kb; Fig. 1 
 
B
 
). For
analysis of cytokine mRNA transcripts, total RNA was extracted
(39) from PMA-stimulated splenocytes (5 ng/ml for 12 h) or whole
unperfused brain and spinal cord. oligo(dT) 12–18 (Boehringer
Mannheim GmbH, Mannheim, Germany) primed cDNA was syn- 
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thesized and analyzed by reverse transcriptase PCR (RT-PCR)
using primers and methods as previously described (29). The
PCR products were size fractionated by electrophoresis on 1.2%
agarose gel containing ethidium bromide.
 
Induction of EAE.
 
EAE was induced actively by subcutaneous
tail base injection of 50 
 
m
 
g of MOG peptide (35-MEVGWYR-
SPFSRVVHLYRNGK-55) in CFA containing 1 mg of heat in-
activated 
 
Mycobacterium tuberculosis
 
 (H37RA; DIFCO Labs., De-
troit, MI). 200 ng of pertussis toxin (LIST Biological Labs., Inc.,
Campbell, CA) was injected intravenously on days 0 and 2. This
disease induction protocol was optimized in WT C57BL/6 mice
by pertussis toxin and MOG peptide dose-ranging experiments.
Animals were observed daily and neurological deficits were quan-
tified on an arbitrary clinical scale: 1
 
1
 
, flaccid tail; 2
 
1
 
, hind limb
weakness or abnormal gait; 3
 
1
 
, severe hind limb weakness with
loss of ability to right from supine; 4
 
1
 
, hind quarter paralysis;
5
 
1
 
, forelimb weakness or moribund; 6
 
1
 
, death. Supplementary
food and water were provided on the cage floor for disabled ani-
mals.
 
Generation of Radiation Bone Marrow Chimeras.
 
Bone marrow
cells, harvested from the long bones of matched donor mice by
flushing with cold PBS, were gently deaggregated through 70
 
m
 
m nylon cell strainers (Becton Dickinson, Franklin Lakes, NJ),
washed, and counted. Recipient animals were preconditioned
with 5.5 Gy gamma radiation on day 2, and again on day 0. Bone
marrow cells (2 
 
3 
 
10
 
7 
 
cells/recipient) were injected intravenously
on day 0. Cage water was supplemented with trimethoprim (50
 
m
 
g/ml)–sulphamethoxazole (0.25 mg/ml) between weeks 2 and
3 after transplantation. As a means of tracking engraftment, recip-
rocal transplantations between TNF
 
2/2
 
 (C57BL/6.Ly5.2) and
C57BL/6.Ly5.1 mice were performed. Peripheral blood was
drawn from recipients after transplantation and analyzed by flow
cytometry for the presence or absence of the Ly5.1 (CD45.1)
congenic marker on leukocytes. Engraftment was considered sat-
isfactory when in excess of 95% of circulating leukocytes ex-
pressed the CD45 marker of donor type.
 
Antibodies.
 
The origins of mAbs specific for mouse CD4,
Mac-1 (CD11b), vascular cell adhesion molecule 1 (VCAM-1),
CD45, TCR-a/b, and isotype-matched control antibodies are
detailed elsewhere (23). Other mAbs were rat anti–I-Ab (M5/
114.15.2; reference 40) provided by G. Halliday (University of
Sydney, Sydney, Australia), rat anti–mouse B220-PE (RA3-6B2;
Caltag Labs., South San Francisco, CA), and biotinylated mouse
anti–mouse Ly5.1 (A20; reference 41) detected by Streptavidin-
FITC (PharMingen, San Diego, CA). Polyclonal rabbit anti–induc-
ible nitric oxide synthase (anti-iNOS; Upstate Biotechnology, Inc.,
Lake Placid, NY) and rabbit IgG control (Vector Labs., Burlin-
game, CA) antibodies were used in immunohistochemical studies.
MOG-specific IgG Determination. Relative serum IgG anti-MOG
35–55 responses were quantified by ELISA as described (23).
Flow Cytometric Analysis. Flow cytometric analysis of bone
marrow engraftment in chimeras was performed on peripheral
blood leukocytes after red blood cell lysis. Cells were incubated
with biotinylated anti-Ly5.1 mAbs and one of the following di-
rectly PE-conjugated mAbs: anti-B220 (B cells), anti–TCR-a/b
(T cells), anti–Mac-1 (monocytes, granulocytes, and NK cells), or
their appropriate controls. Ly5.11 cells were identified using a
second step incubation with Streptavidin-FITC. CNS-associated
leukocytes were isolated from collagenase/DNase-digested whole
CNS tissue after heparin-saline perfusion of animals, and Percoll
gradient density purification steps were performed as described
(42). Purified cells were incubated with directly conjugated anti-
CD45-PE and anti–TCR-a/b–FITC antibodies, or appropriate
controls. Flow cytometric data was acquired on a FACScanÒ
(Becton Dickinson, San Jose, CA) and analyzed using CELL
QuestTM (Becton Dickinson, San Jose, CA) software.
Immunohistology and Neuropathology. Dissected specimens of
nonperfused whole brain were embedded in OCT compound
(Tissue Tek, Miles, Inc., Elkhart, IN), frozen in liquid nitrogen
vapor, and stored at 2708C until use. Serial cryostat sections (6 mm)
were stained with various mAbs via the immunoperoxidase tech-
nique, and counterstained with hemotoxylin (23). Sections were
photographed using transmitted light interference contrast optics.
Demyelination studies were performed on CNS tissue obtained
from animals perfused with warm PBS followed by 4% parafor-
maldehyde and 2.5% glutaraldehyde in PBS, and processed as
previously described (23). Sections were examined and photo-
graphed using standard bright-field optics.
Treatment of Mice with TNFR–IgG. The activities of LTa3
and TNF were inhibited in vivo by injection of a recombinant
fusion protein consisting of the mouse p55 TNFR–IgG (provided
by J. Ghrayeb and B. Scallon, Inc., Centocor, Malvern, PA). Mol-
ecules of this type have been shown to bind and inhibit mouse se-
creted LTa (43) and TNF (44). TNFR–IgG was delivered at var-
ious time points throughout the course of EAE by intraperitoneal
injection at a dose of 500–1,000 mg/injection. PBS or equivalent
amounts of human IgG (protein A affinity purified from normal
serum) were used as controls. 
Results
Generation of C57BL/6 LTa2/2 Mice. The injection of
one targeted C57BL/6 ES cell clone into blastocysts of the
BALB/c strain resulted in the birth of chimeric mice, all of
which transmitted through the germ line after mating with
C57BL/6 mice. Founder heterozygous mice were chosen,
interbred, and screened by Southern blot. LTa2/2 mice
were born in the expected Mendelian ratio of 1:2:1 and
were sustained as a homozygous line on the C57BL/6
background (Fig. 1 B). The successful disruption of the
gene encoding LTa was confirmed by RT-PCR. LTa-
specific mRNA was not detectable in PMA-activated sple-
nocytes (Fig. 1 C), whereas expression of TNF mRNA was
readily detected. By contrast, LTa transcripts were de-
tected in stimulated cells from TNF2/2 mice, but neither
TNF nor LTa transcripts from TNF/LTa2/2 mice (Fig. 1
C). LTa2/2 mice bred well and were grossly normal.
Closer inspection of the lymphoid organs showed the ex-
pected absence of peripheral lymph nodes and Peyer’s
patches, a disturbed splenic architecture, and peripheral
blood lymphocytosis (20, 21, data not shown). LTa2/2
mice lack both secreted LTa3 and membrane LTa1b2 forms
of LT because functional surface expression of LTb de-
pends on the presence of LTa (17).
The Course of EAE in WT C57BL/6, TNF2/2, and
TNF/LTa2/2 Mice. Subcutaneous immunization of WT
C57BL/6 mice with 50 mg of MOG 35–55 in CFA, and
pertussis toxin intravenously on days 0 and 2, resulted in a
highly reproducible severe acute meningoencephalomyeli-
tis, with clinical signs of rapidly progressing, ascending
symmetrical motor deficits, appearing on or around day 10.
Clinical disease was present for z15 d and spontaneously1520 Autoimmune Inflammation in LT and TNF Gene-targeted Mice
remitted (Fig. 2) to leave a mild, chronic, nonrelapsing def-
icit (approximately disease score 1). Disease in TNF2/2
mice (Fig. 2) was delayed in onset by z6 d. Once estab-
lished, however, clinical deficits in these mice progressed in
a parallel course to an equivalent mean peak severity, but
were of a reduced overall duration when compared with
WT, as we have previously described (23).
C57BL/6 TNF/LTa2/2 mice, which lack peripheral
lymph nodes and exhibit a range of immune deficiencies
(29, 45), were entirely resistant to clinical disease induction
by our standard immunization protocol (Fig. 2). Similarly,
immunization of RAG 12/2 mice, which lack mature lym-
phocytes, also resulted in no clinical syndrome (Fig. 2 and
Table 1, A–C). Thus, disease resistance in TNF/LTa2/2
mice could indicate either a critical role for LT, or the con-
sequences of a broadly deficient immune system as exem-
plified by the RAG-12/2 mice. Determination of the role
of LT in EAE required the reconstitution of immunocom-
petent peripheral lymphoid organs by other means.
Characteristics of Radiation Bone Marrow Chimeras. Chime-
ras were generated using a split-dose irradiation protocol
and large bone marrow inoculum to ensure complete con-
version of the recipient hemopoietic compartment to do-
nor type. Two types of radiation bone marrow chimeras
were generated. The first involved the transfer of WT or
LTa2/2 bone marrow to RAG-12/2 mice (WT®RAG,
LT®RAG). This chimeric system tested whether the ab-
sence of both forms of LT, but the presence of TNF, af-
fected susceptibility to EAE. The absence of lymphocytes
in RAG-12/2 mice guaranteed that any T or B cells in
these chimeras were LT negative. These mice were used
for EAE studies 8 wk after bone marrow reconstitution. A
further chimera, generated by the transfer of TNF2/2 bone
marrow to RAG-12/2 recipients (TNF®RAG), was used
as a control for the CNS cytokine mRNA expression anal-
ysis (see below).
The second series of chimeras involved the transfer of
TNF/LTa2/2 bone marrow (completely deficient in both
TNF and LT) to TNF2/2 recipient mice (TNF/LT®TNF)
or appropriate controls (WT®WT, TNF®TNF). This ar-
rangement tested how the absence of both TNF and LT af-
fected susceptibility to EAE and, in particular, if LT was re-
sponsible for the EAE observed in TNF2/2 mice (23). Each
type of radiation bone marrow chimera was examined for
the presence of lymphoid tissue after experimental use. As ex-
pected, lymph nodes were repopulated in all mice (not shown).
The efficacy of the irradiation and reconstitution protocol
for engraftment was examined in parallel using a CD45 con-
genic  marker (Ly5.1.WT®TNF, and TNF®Ly5.1.WT)
and serial flow cytometric analyses of peripheral blood leu-
kocytes (Fig. 3 A). At the time of immunization, in excess
of 95% of circulating a/b-TCR1, B2201, and CD11b1
(Mac-1) cells were of donor type. Importantly, engraftment
proceeded irrespective of the TNF status of the donor or
recipient (Fig. 3 A).
Antibody is important in the development of demyelina-
tion (46). To determine whether antibody responses in chi-
meric mice had been normalized, serum samples were col-
Figure 1. Generation of C57BL/6 LTa2/2 mice. (A) LTa gene target-
ing strategies. The LTa gene is indicated in relation to TNF and LTb
genes. All are within the murine H-2 locus on chromosome 17. Tran-
scription direction is indicated by arrows. A neomycin resistance cassette
was inserted in sense direction into a unique ApaI site in exon 2 of the
LTa gene to produce the targeting construct that was transfected in
Bruce4 C57BL/6 ES cells. The predicted targeted allele is illustrated. (B)
Southern blot of genomic DNA extracted from peripheral blood of ho-
mozygous, heterozygous, or WT mice confirming homozygous muta-
tions of the LTa gene. A PstI site introduced by the neomycin resistance
cassette was used to differentiate between mutated and WT alleles. (C)
RT-PCR confirms absence of LTa transcripts. RNA was derived from
PMA-stimulated splenocytes from WT, LTa2/2, TNF2/2, or TNF/
LTa2/2 mice (29), and analysis by RT-PCR for TNF, LTa, and b-actin
transcripts. b-actin PCR product, 304 bases; TNF PCR product, 256
bases; LTa PCR product, 229 bases.
Figure 2. Natural history of MOG 35–55 peptide-induced EAE in
C57BL/6 strain mice. Shown are disease courses of individual mice that
represent groups of WT (n . 20), TNF2/2 (n . 20), TNF/LTa2/2 (n 5
5), and RAG-12/2 (n 5 3) mice immunized on day 0. See text for expla-
nation of the clinical disease score.1521 Riminton et al.
lected from WT®WT, TNF®TNF, and TNF/LT®TNF
mice at day 23 after immunization with MOG 35–55/
CFA/pertussis toxin and were assayed by ELISA. Peptide-
specific IgG responses were observed in all mice (Fig. 3 B)
with responses in TNF/LT-deficient mice at least as great
as in WT mice.
EAE Course in Mice Lacking LT Alone. WT®RAG and
LT®RAG mice were immunized according to the stan-
dard protocol. Disease onset, rate of progression, and peak
severity were equivalent in both groups (Fig. 3 C and Ta-
ble 1 D) indicating no unique role for LT in the clinical
neurological deficit. Disease course is illustrated up to day
22 only, due to the ethical requirement to kill severely af-
fected animals. The day 15 onset of disease in both groups
(rather than day 10 in unmanipulated animals, see Fig. 2) is
probably due to the use of these mice only 8 wk after trans-
plantation when T cell reconstitution to normal levels may
not have occurred (see Fig. 3 legend). Irrespective of the
time of use, all lymphocytes in these chimeras were of do-
nor type.
EAE in Chimeras Lacking Both LT and TNF. To explore
the possibility that the activity of LT in EAE was obscured
by the compensatory influence of normal TNF expression
in Fig. 3 C, the role of LT was examined in a TNF-defi-
cient system (TNF/LT®TNF). The clinical course of dis-
ease in WT®WT and TNF®TNF mice followed that
predicted by previous experiments (Fig. 3 D and Table 1
E), reproducing the delay in disease onset seen in Fig. 2 and
validating this experimental approach. Remarkably, TNF/
LT®TNF mice followed a course of disease that was indis-
tinguishable from TNF®TNF mice, with no augmenta-
tion of the delay in onset, normal slope of the disease pro-
gression curve, and normal peak severity of disease (Fig. 3
D). Of those mice allowed to continue on to recovery, a
normal resolution of clinical deficits occurred (data not
shown). This result excluded the possibility that an impor-
tant activity of LT in the course of EAE in the LT®RAG
experiment (Fig. 3 C) was obscured by the compensations
of TNF.
CNS LT and TNF mRNA Expression at the Peak of Dis-
ease Severity. The use of the Ly5 markers established the
validity of this approach for effective reconstitution of the
hemopoietic compartment in recipients. The most rigorous
determination of cytokine expression within the CNS itself
is RT-PCR analysis, and this was applied to mRNA ex-
tracted from inflamed CNS tissue (Fig. 4). LTa message
was abundantly expressed in the CNS of all EAE-affected
animals with the exception of the TNF/LT®TNF and
LT®RAG chimeras, consistent with the hemopoietic ori-
gin of this cytokine. Likewise, LTa expression was seen in
Table 1. Summary of Experimental Outcomes
Label
Mice
(all C57BL/6*)
Treat-
ment Control
LN‡ and Ig§
status Purpose
Disease course
compared to
control Figure
A TNF2/2 – WT Intact Absent TNF Delayed 2
B TNF/LTa2/2 – WT LN absent, Ig de- Absence of LTa Not susceptible 2
ficient; refer- and TNF to EAEi
ences 20, 29, 45
C RAG-12/2 – WT LN anlage only,  No mature T or B cells Not susceptible 2
Ig deficient;  to EAEi
reference 32
D Chimera: – WT®RAG Reconstituted LT deficiency in TNF- Unaltered 3 C
LT®RAG competent mice, with
reconstituted immunity
E Chimera: – WT®WT or Reconstituted Deficiency of both LT  Delayed,  3 D
TNF/LT®TNF TNF®TNF and TNF, with reconsti- equivalent to
tuted immunity the absence of
TNF alone
F WT TNFR– WT treated with Intact Inhibition of TNF Delayed 6 A
IgG PBS or human IgG and LTa3
G TNF2/2 TNFR– TNF2/2 treated Intact Inhibition of LTa3 in Unaltered 6 C
IgG with PBS the absence of TNF
*TNF2/2, TNF/LTa2/2, and LTa2/2 mice were generated by gene targeting directly in C57BL/6 ES cells.
‡Lymph node status.
§Serum immunoglobulin status. See also Fig. 3 B.
iNot susceptible to MOG 35-55–induced EAE using our standard disease induction protocol, optimized in WT C57BL/6 mice.1522 Autoimmune Inflammation in LT and TNF Gene-targeted Mice
the unperfused normal WT CNS (Fig. 4), but not in per-
fused WT tissue (data not shown). TNF mRNA expression
was clearly evident in the CNS of all experimental groups,
with the exception of the TNF®TNF and TNF/LT®TNF
chimeras (data not shown). As expected, abundant expres-
sion of LTa was found in the TNF®RAG chimera (Fig.
4), but also abundant TNF message (data not shown), con-
sistent with TNF production by nonhemopoietic, radia-
tion-resistant CNS structures, such as microglia and astro-
cytes (47). Similarly, a trace amount of LTa message was
sometimes observed in the CNS from TNF/LT®TNF
and LT®RAG chimeras at the peak of disease (Fig. 4),
most likely due to low level LTa production by activated
glia (47). It is improbable that LTa expression of this na-
ture is significant within the terms of these experiments, an
assertion supported by further studies using TNFR–IgG
(see below).
Inflammatory Cell Recruitment to the CNS in the Absence of
TNF and LT. The influence of individual cytokines on
the number of inflammatory cells recruited to the entire
CNS was examined by flow cytometric analysis of leuko-
cytes extracted from the whole perfused CNS of chimeras
(Fig. 5, A and B). The magnitude of inflammatory cell re-
cruitment was comparable in WT®WT, TNF®TNF, and
TNF/LT®TNF chimeras (Fig. 5 A). Immunophenotyp-
ing was then performed to evaluate the possibility that
TNF or LT influenced the relative proportions of individ-
ual inflammatory cell subsets. Fig. 5 B shows that, in the
absence of TNF, there was a relative increase in the pro-
portion of a/b-TCR1 cells as a percentage of total CD451
cells, comprising populations of monocyte–macrophages, T
cells, and microglia (42). Most importantly, differences
were not observed between the TNF®TNF and TNF/
LT®TNF chimeras (Fig. 5 B, middle and right) indicating
no additional alteration of the infiltrate imposed by the ab-
sence of LT. 
Neuropathological Studies at Peak of Disease Severity. To ex-
amine the influence of TNF and LT on the formation of
CNS inflammatory lesions, immunohistochemical studies
using CD45 staining of cells within CNS tissue were per-
formed (Fig. 5, C–F). In all specimens, large numbers of
CD451 cells could be identified at the peak of disease. Le-
sions within the CNS of WT®WT chimeras exhibited the
normal appearance of cells moving freely from the vessel
lumen into the perivascular space, and beyond into the
CNS parenchyma (Fig. 5 C). In contrast, the perivascular
cuffs of TNF®TNF and TNF/LT®TNF chimeras (Fig.
5, D and E) showed a striking perivascular congestion of
cells. Significantly, the diffuse appearance of lesions within
the CNS of LT®RAG chimeras (Fig. 5 F) clearly indi-
cated that this role is not shared by LT. Moreover, despite
abundant LT expression in the TNF®TNF mice (Fig. 4),
normal cell movement within the CNS parenchyma failed
Figure 3. EAE in LTa- and TNF/LTa-deficient radiation bone mar-
row chimeric mice. (A) Reconstitution analysis showing the proportion
of peripheral blood leukocytes bearing the CD45-congenic marker of do-
nor type at 14 wk after bone marrow transplantation. T cell reconstitution
was slower than B cells or Mac-11 cells, so this period of time was al-
lowed for complete reconstitution in all compartments. White bars, a/b T
cells; gray bars, B cells; black bars, Mac-11 cells. (B) Representative serum
MOG 35–55 peptide–specific IgG responses in individual EAE-affected
chimeras, compared with normal mouse serum (NMS) 23 d after standard
MOG/CFA/pertussis immunization. Optical density at 405 nm for serial
serum dilutions of individual animals is shown. (C) Mean EAE clinical
score in WT®RAG (n 5 3) and LT®RAG (n 5 4) radiation bone mar-
row chimeras on days after immunization. (D) Mean EAE clinical score
in WT®WT (n 5 8), TNF®TNF (n 5 10), and TNF/LT®TNF (n 5
15) radiation bone marrow chimeras on days after immunization.
Figure 4. LTa mRNA ex-
pression in the inflamed CNS of
radiation bone marrow chi-
meric mice. RNA was ex-
tracted from the unperfused
whole CNS of a normal unim-
munized C57BL/6 mouse (Nor-
mal WT) and from various chi-
meras, all EAE-affected and matched for disease severity (clinical score of
5). See Materials and Methods for PCR primers used.1523 Riminton et al.
Figure 5. Characterization of CNS inflammation. (A) Total numbers of leuko-
cytes extracted from the perfused whole CNS at day 23. All animals were matched
for disease score of 5/6 at the time of analysis. Each bar represents a single animal.
WT®WT (black bar), TNF®TNF (white bars), and TNF/LT®TNF (hatched bars).
Horizontal line, typical number of leukocytes extracted from the normal, perfused
CNS of the C57BL/6 mouse. (B) T cell inflammation in the absence of TNF or
TNF/LT. CNS-associated leukocytes were derived from individual animals as in A.
Cells were stained for CD45 and TCR-a/b, and all CD45-negative cells were ex-
cluded by gating. Histograms show TCR-a/b expression of CD451 cells. (C–F)
Altered nature of inflammatory infiltrate in TNF2/2 mice. Cryostat sections of spinal
cord from indicated chimeras were stained for CD45 to reveal all inflammatory cells.
All animals were matched for disease (score 5/6) at the time of harvest of CNS tis-
sues. (G) Histopathological study using toluidine blue staining of spinal cord from
TNF/LT®TNF chimeric mice. Tissue taken at day 40 after immunization is shown.
Demyelinated fibres, arrows; lipid-laden macrophages (“glitter” cells), arrowheads.
Bars: (C–F) 120 mm; and (G) 60 mm.1524 Autoimmune Inflammation in LT and TNF Gene-targeted Mice
to occur (Fig. 5 D) in the absence of TNF. No alteration in
the magnitude or distribution of cells expressing MHC class
II, Mac-1 (CD11b), CD4, iNOS, or vascular cell adhesion
molecule 1 could be observed in the absence of LT (data
not shown). The normal expression of iNOS in the TNF/
LT®TNF brain indicated that the activation of this critical
macrophage effector was not dependent on the activities of
either TNF or LT (not shown).
A neuropathological study of fixed tissues from TNF/
LT®TNF CNS at day 40 demonstrated clear primary de-
myelination, despite the lack of both TNF and LT (Fig. 5
G). Lipid-filled glitter cells (phagocytic macrophages), which
are pathognomonic of inflammatory demyelinating disease,
were also present. 
Collectively, these findings confirm normal histopatho-
logical features of EAE, despite the lack of LT. The abnor-
mal features described above are explained by the absence
of TNF alone.
TNFR–IgG Alters the Course of EAE in WT, but Not
TNF2/2, Mice. The effect of TNF and LTa3 blockade on
EAE susceptibility in otherwise unmanipulated WT mice
was examined. Very high doses of TNFR–IgG adminis-
tered immediately before the onset of clinical neurological
deficits resulted in a delay in the onset of disease when
compared with animals treated with PBS (Fig. 6 A and Ta-
ble 1 F), in a manner that was analogous to findings in the
TNF2/2 animals (Fig. 2). Similarly, the rate of disease pro-
gression and the eventual peak severity of disease was not
affected by treatment, even when treatment was continued
through the emergence of clinical signs. This effect de-
pended exclusively on the TNFR component of the fusion
protein (Fig. 6 B).
As an alternative means of studying the activities of LTa3
in a TNF-deficient system, LTa3 was blocked in TNF2/2
mice by administration of TNFR-IgG (Fig. 6 C and Table
1 G). Disease onset and disease severity in both human IgG
control– and TNFR-IgG–treated mice was identical, and
although some divergence of the disease curves was ob-
served, there was no indication that LTa3 inhibition influ-
enced its course. Again, most mice were killed at the peak
of disease to conform with ethical requirements. Mice from
both groups that were followed through to disease resolu-
tion progressed similarly.
Discussion
It is widely accepted that the secreted (LTa3) or cell
membrane (LTa1b2) forms of LT exhibit TNF-like prop-
erties, particularly since LTa3 can bind to the TNFRs (14).
A feature common to gene-targeted mice lacking TNF
(29, 48), LTa (20), or LTb (26), or of mice in which the
action of these cytokines is blocked during gestation (49), is
that all exhibit changes in lymphoid structures. Neverthe-
less, the magnitude and precise nature of anatomical
changes in TNF2/2 versus LTa2/2 or LTb2/2 mice are
largely nonoverlapping, indicating distinct in vivo func-
tions for these molecules. The results of this study, in
which the roles of LT and TNF in autoimmune inflamma-
tion were compared, are entirely consistent with the view
that TNF and LT are functionally distinct entities in vivo. 
In these studies, the clinical and pathological course of
EAE was influenced in a striking way by the absence of
TNF (Fig. 2 and Table 1 A), an outcome that appears to be
Figure 6. Influence of TNFR–IgG treatment on the clinical course of
EAE in WT and TNF2/2 C57BL/6 mice. (A) Mean EAE clinical score of
MOG 35-55–induced EAE in WT mice, each treated by intraperitoneal
injection with high dose TNFR–IgG (n 5 10) on days 8 (500 mg), 11 (1 mg),
and 14 (1 mg) after immunization (day 0) or an equivalent volume of PBS
on these days (n 5 10). (B) Mean EAE clinical score of MOG 35-55–
induced EAE in WT mice treated by intraperitoneal injection with affin-
ity purified human IgG (n 5 4, 500 mg, days 11 and 14) or an equivalent
volume of PBS on days 11 and 14 (n 5 3). (C) Mean EAE clinical score
of MOG 35-55–induced EAE in TNF2/2 mice treated by intraperitoneal
injection with TNFR–IgG (n 5 4) or affinity purified human IgG (n 5
3). Mice received 500 mg TNFR–IgG or human IgG immediately after
the onset of clinical signs and again 4 d later.1525 Riminton et al.
explained by the abnormal movement of inflammatory cells
within the target tissue early in the clinical course (23).
This phenotype is not due to the failure of inflammatory
cell recruitment per se, because normal numbers of CD451
cells can be extracted from the perfused whole CNS of
mice lacking TNF at any given time point after immuniza-
tion (Fig. 5 A; reference 23). TNF-dependent cell adhesion
events are not, therefore, a satisfactory or complete expla-
nation. The importance of TNF in the control of cell
movement within the tissue is supported by the observa-
tion that even when disease is established in TNF-deficient
mice, leukocytes fail to move freely from a perivascular lo-
cation into the CNS parenchyma (compare Fig. 5 C
[WT®WT] with Fig. 5 D [TNF®TNF]). This consoli-
dates the impression that the normal formation of the in-
flammatory lesion depends upon an activity of TNF on the
abluminal side of the CNS vascular endothelium as sug-
gested previously (23). Possible mechanisms to explain this
effect include a role for TNF in the generation of chemoat-
tractant gradients (50), in the digestion of the extracellular
matrix (51, 52), or in the final effector phase activation of
the recruited inflammatory cells. The relative reduction in
the proportion of non-T inflammatory cells in mice lacking
TNF (Fig. 5 B) or in rats treated with TNFR–IgG (12)
may also indicate that the T cell is less dependent on TNF
for normal tissue infiltration. Irrespective of these consider-
ations, primary demyelination, which is the characteristic
end point of the pathological process and which depends
upon many of the coordinated processes of acquired im-
munity including antibody production, proceeds without
inhibition in the absence of TNF (Fig. 5 G; reference 23).
Clearly, LTa could not compensate for the abnormal
course of disease in TNF2/2 mice (Fig. 2), although it was
possible that the emergence of disease, when it occurred,
was indeed a LT-dependent process. To pursue this fur-
ther, we adopted a combination of approaches, the results
of which are summarized in Table 1. The use of direct im-
munization in LT-deficient mice was precluded by the fail-
ure of these mice to respond to a standard disease induction
protocol (Fig. 2 and Table 1 B), an explanation being the
absence of peripheral lymphoid organs. Thus, we sought to
examine the role of LT in this model by the use of gene-
targeted radiation bone marrow chimeric mice.
The first set of experiments (LT®RAG; Fig. 3 C and
Table 1 D) demonstrated that LT has no unique role in the
clinical manifestations of disease. It was possible, however,
that TNF expression compensated for the absence of LT in
this experiment. It would follow, therefore, that in a TNF-
deficient mouse, the role of LT might become apparent,
although such an activity would then be regarded as fully
redundant to TNF. Thus, a second set of studies was per-
formed using TNF/LT®TNF chimeras (Fig. 3 D and Ta-
ble 1 E). These experiments showed that the absence of LT
had no additional influence on the clinical course of EAE
in TNF-deficient mice. The concept that TNF and LT
have redundant functions in autoimmunity therefore fails
to be supported by these observations, which have been
made despite the knowledge that both cytokines are abun-
dantly expressed in the inflammatory lesion (Fig. 4 and
text) and share common receptor binding (14). Although
LTa1b2–LTbR interactions do seem to elicit a cytotoxic
signal (22), it seems likely that the importance of the LTa3–
TNFR interaction in cytotoxicity in the mouse has been
overestimated (43). The use of LTa2/2 mice in this study,
which lack both the secreted and membrane forms of LT, in-
dicates that neither plays an indispensable role in the pro-
cesses leading to clinical manifestations of EAE. 
The ability of therapeutic inhibition of TNF and LT to
modulate, and in some cases ablate, the clinical manifesta-
tions of EAE is well described (11–13) and has represented
the most persuasive source of experimental evidence for a
key role for these molecules in the pathogenesis of CNS
autoimmune inflammation. In the Lewis rat, inhibition of
TNF and LTa3 resulted in abrogation of disease, but did
not impede T lymphocyte accumulation within the CNS
(12, 53). The results obtained after the administration of
TNFR–IgG to WT C57BL/6 mice (Fig. 6 A and Table 1
F) precisely reproduced the clinical outcome observed in
TNF2/2 mice (Fig. 2 and Fig. 3 D). Differences in the ex-
tent of disease inhibition by TNFR–IgG between other
models and MOG 35-55–induced EAE in C57BL/6 mice
may be due to the severity of the clinical disease and partic-
ularly the development of substantial primary demyelina-
tion in the MOG model. These findings reinforce the need
for a reevaluation of the influences of TNF inhibition in
other autoimmune disease models, particularly with respect
to the nature of the inflammatory process.
In summary, once factors such as immune competence
and genetic heterogeneity are accounted for, EAE in the
absence of LT progresses in a manner that is indistinguish-
able from controls, as measured by the clinical manifesta-
tions of disease, the generation of inflammatory lesions, and
specific target damage in the form of demyelination. On
the other hand, the lack of TNF alone results in profound
changes in the movement of leukocytes within the CNS
(Fig. 5) and LT appears unable to compensate for its ab-
sence (Fig. 4 and Fig. 5 D). These findings do not support
the concept that LT is an independent mediator of acute
autoimmune inflammatory processes. Therefore, the pur-
pose of abundant LT expression within these lesions is un-
explained. The capacity of transgenic overexpression of
LTa to generate organized ectopic lymphoid structures
within tissues (54), raises the possibility that LT establishes
the cellular architecture of chronic inflammatory lesions.
Further studies investigating the role of LT in the late
phases of autoimmune inflammation are warranted.
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